Vindesine

Base Information

• Chemical Name: Vindesine
• CAS No.: 53643-48-4
• Molecular Formula: C43H55 N5 O7
• Molecular Weight: 753.939
• European Community (EC) Number: 261-984-7,258-682-2
• DSSTox Substance ID: DTXSID6023739
• Nikkaji Number: J24.547J
• Wikipedia: Vindesine
• Wikidata: Q416660
• NCI Thesaurus Code: C934,C935
• Metabolomics Workbench ID: 42696
• ChEMBL ID: CHEMBL219146
• Mol file: 53643-48-4.mol

Synonyms:Compound 112531;Desacetylvinblastine Amide;Eldisine;Enison;NSC 245467;NSC-245467;NSC245467;Sulfate, Vindesine;Vindesin;Vindesine;Vindesine Sulfate

Chemical Property of Vindesine

Chemical Property:

• Melting Point: 230-232oC
• Boiling Point: °Cat760mmHg
• PKA: pKa (DMF 66%) 5.39, 7.36; (H2O) 6.04, 7.67(at 25℃)
• Flash Point: °C
• PSA: 164.82000
• Density: 1.41g/cm³
• LogP: 3.37350
• XLogP3: 2.7
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 7
• Exact Mass: 753.41014911
• Heavy Atom Count: 55
• Complexity: 1570

Purity/Quality:

98%,99%, ^*data from raw suppliers

Vindesine ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
• Isomeric SMILES: CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
• Recent ClinicalTrials: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
• Recent EU Clinical Trials: A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT versus TKI, blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders (GMALL-EVOLVE)
• Recent NIPH Clinical Trials: Randomized, comparative clinical study of cisplatin and docetaxel combination chemotherapy and mitomycin, vindesine and cisplatin (MVP) combination chemotherapy with concurrent thoracic radiation therapy for locally advanced unresectable non-small-cell lung cancer (OLCSG0007)
• Uses: Antineoplastic.
• Therapeutic Function: Antineoplastic

Technology Process of Vindesine

There total 2 articles about Vindesine which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ 18-(3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydro-aspidospermidin-15-yl)-4-hydroxy-5,18-seco-ibogamine-18-carboxylic acid methyl ester (53643-48-4)

Guidance literature:

Vinblastinsulfat, 1. NH4OH 2. MeOH, NH3;

DOI:10.1021/jm00199a016

Reference yield:

→ 18-(3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydro-aspidospermidin-15-yl)-4-hydroxy-5,18-seco-ibogamine-18-carboxylic acid methyl ester (53643-48-4)

Guidance literature:

aus C3-carboxhydrazid und NaNO2/HCl, NH3;